Compounds > 3'-Hydroxy-5,7,4'-trimethoxy-4-phenylcoumarin
Page last updated: 2024-11-12

3'-Hydroxy-5,7,4'-trimethoxy-4-phenylcoumarin

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Cross-References

ID SourceID
PubMed CID10336603
CHEMBL ID153529
CHEBI ID193339
SCHEMBL ID12986381

Synonyms (6)

Synonym
CHEMBL153529
LMPK12100051
3'-hydroxy-5,7,4'-trimethoxy-4-phenylcoumarin
4-(3-hydroxy-4-methoxyphenyl)-5,7-dimethoxychromen-2-one
CHEBI:193339
SCHEMBL12986381
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
neoflavonoidAny 1-benzopyran with an aryl substituent at position 4. The term was originally restricted to natural products, but is now also used to describe semi-synthetic and fully synthetic compounds.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Bioassays (30)

Assay IDTitleYearJournalArticle
AID595709Modulation of P-gp in human K562 cells assessed as intracellular accumulation of daunorubicin at 30 uM after 30 mins by flow-cytometry2011Journal of medicinal chemistry, May-12, Volume: 54, Issue:9
Synthesis and biological evaluation of 4-arylcoumarin analogues of combretastatins. Part 2.
AID595714Cytotoxicity against drug-resistant human HCT116 cells overexpressing BCRP after 48 hrs by MTT assay2011Journal of medicinal chemistry, May-12, Volume: 54, Issue:9
Synthesis and biological evaluation of 4-arylcoumarin analogues of combretastatins. Part 2.
AID47643Inhibitory activity against CEM human leukemia cell line2003Journal of medicinal chemistry, Dec-04, Volume: 46, Issue:25
Synthesis and biological evaluation of 4-arylcoumarin analogues of combretastatins.
AID468176Antileishmanial activity against Leishmania donovani MHOM/IN/80/DD8 amastigotes infected in human THP1 cells assessed as decrease of infected macrophages after 72 hrs by Giemsa staining2010European journal of medicinal chemistry, Mar, Volume: 45, Issue:3
Synthesis and antiprotozoal activity of 4-arylcoumarins.
AID595713Cytotoxicity against human HBL100 cells after 72 hrs by MTT assay2011Journal of medicinal chemistry, May-12, Volume: 54, Issue:9
Synthesis and biological evaluation of 4-arylcoumarin analogues of combretastatins. Part 2.
AID595722Cell cycle arrest in drug-resistant human HCT116 cells overexpressing BCRP assessed as accumulation at G2/M phase at 10 uM after 24 hrs by FACS-flow cytometry (Rvb = 30 +/- 4 %)2011Journal of medicinal chemistry, May-12, Volume: 54, Issue:9
Synthesis and biological evaluation of 4-arylcoumarin analogues of combretastatins. Part 2.
AID1312639Cytotoxicity against human CEM cells assessed as cell growth inhibition measured after 72 hrs by CellTiter-96 AQueous one solution cell proliferation assay2016European journal of medicinal chemistry, Aug-25, Volume: 119Recent developments of C-4 substituted coumarin derivatives as anticancer agents.
AID468178Antileishmanial activity against Leishmania donovani MHOM/IN/80/DD8 promastigotes assessed as parasite viability after 48 hrs by Alamar blue assay2010European journal of medicinal chemistry, Mar, Volume: 45, Issue:3
Synthesis and antiprotozoal activity of 4-arylcoumarins.
AID256508Inhibitory activity against Topoisomerase I2005Bioorganic & medicinal chemistry letters, Oct-01, Volume: 15, Issue:19
A new synthesis of isoaurones: cytotoxic activity of compounds related to the alleged structure of isoaurostatin.
AID595715Cytotoxicity against drug-sensitive human HCT116 cells after 48 hrs by MTT assay2011Journal of medicinal chemistry, May-12, Volume: 54, Issue:9
Synthesis and biological evaluation of 4-arylcoumarin analogues of combretastatins. Part 2.
AID1312640Inhibition of lamb brain tubulin polymerization by spectrophotometric method based microtubule assay2016European journal of medicinal chemistry, Aug-25, Volume: 119Recent developments of C-4 substituted coumarin derivatives as anticancer agents.
AID468177Selectivity index, ratio of IC50 for human THP1 cells to IC50 for Leishmania donovani MHOM/IN/80/DD8 amastigotes2010European journal of medicinal chemistry, Mar, Volume: 45, Issue:3
Synthesis and antiprotozoal activity of 4-arylcoumarins.
AID595711Cytotoxicity against drug-sensitive human K562 cells after 48 hrs by MTT assay2011Journal of medicinal chemistry, May-12, Volume: 54, Issue:9
Synthesis and biological evaluation of 4-arylcoumarin analogues of combretastatins. Part 2.
AID595718Cell cycle arrest in drug-sensitive human HCT116 cells assessed as accumulation at G2/M phase at 0.1 uM after 24 hrs by FACS-flow cytometry (Rvb = 32+/- 3 %)2011Journal of medicinal chemistry, May-12, Volume: 54, Issue:9
Synthesis and biological evaluation of 4-arylcoumarin analogues of combretastatins. Part 2.
AID595717Cell cycle arrest in drug-resistant human K562 cells overexpressing P-gp assessed as accumulation at G2/M phase at 0.1 uM after 24 hrs by FACS-flow cytometry (Rvb = 18 +/- 2 %)2011Journal of medicinal chemistry, May-12, Volume: 54, Issue:9
Synthesis and biological evaluation of 4-arylcoumarin analogues of combretastatins. Part 2.
AID595725Inhibition of lamb tubulin assembly assessed as half inhibitory molar ratio of compound to tubulin by fluorimetry2011Journal of medicinal chemistry, May-12, Volume: 54, Issue:9
Synthesis and biological evaluation of 4-arylcoumarin analogues of combretastatins. Part 2.
AID595719Cell cycle arrest in drug-resistant human HCT116 cells overexpressing BCRP assessed as accumulation at G2/M phase at 0.1 uM after 24 hrs by FACS-flow cytometry (Rvb = 30 +/- 4 %)2011Journal of medicinal chemistry, May-12, Volume: 54, Issue:9
Synthesis and biological evaluation of 4-arylcoumarin analogues of combretastatins. Part 2.
AID468175Cytotoxicity against human THP1 cells assessed as cell viability after 72 hrs by Alamar blue assay2010European journal of medicinal chemistry, Mar, Volume: 45, Issue:3
Synthesis and antiprotozoal activity of 4-arylcoumarins.
AID468182Cytotoxicity against human HBL100 cells2010European journal of medicinal chemistry, Mar, Volume: 45, Issue:3
Synthesis and antiprotozoal activity of 4-arylcoumarins.
AID468181Cytotoxicity against human CEM cells2010European journal of medicinal chemistry, Mar, Volume: 45, Issue:3
Synthesis and antiprotozoal activity of 4-arylcoumarins.
AID595726Binding affinity at lamb tubulin by spectrofluorimetric analysis2011Journal of medicinal chemistry, May-12, Volume: 54, Issue:9
Synthesis and biological evaluation of 4-arylcoumarin analogues of combretastatins. Part 2.
AID595720Cell cycle arrest in drug-sensitive human K562 cells assessed as accumulation at G2/M phase at 10 uM after 24 hrs by FACS-flow cytometry (Rvb = 23 +/- 2 %)2011Journal of medicinal chemistry, May-12, Volume: 54, Issue:9
Synthesis and biological evaluation of 4-arylcoumarin analogues of combretastatins. Part 2.
AID255898Cytotoxic activity against human non-small lung carcinoma cell line H4602005Bioorganic & medicinal chemistry letters, Oct-01, Volume: 15, Issue:19
A new synthesis of isoaurones: cytotoxic activity of compounds related to the alleged structure of isoaurostatin.
AID595710Modulation of BCRP in human HCT116 cells assessed as intracellular accumulation of mitoxantrone at 10 uM after 30 mins by flow-cytometry2011Journal of medicinal chemistry, May-12, Volume: 54, Issue:9
Synthesis and biological evaluation of 4-arylcoumarin analogues of combretastatins. Part 2.
AID595716Cell cycle arrest in drug-sensitive human K562 cells assessed as accumulation at G2/M phase at 0.1 uM after 24 hrs by FACS-flow cytometry (Rvb = 23 +/- 2 %)2011Journal of medicinal chemistry, May-12, Volume: 54, Issue:9
Synthesis and biological evaluation of 4-arylcoumarin analogues of combretastatins. Part 2.
AID595721Cell cycle arrest in drug-resistant human K562 cells overexpressing P-gp assessed as accumulation at G2/M phase at 10 uM after 24 hrs by FACS-flow cytometry (Rvb = 18 +/- 2 %)2011Journal of medicinal chemistry, May-12, Volume: 54, Issue:9
Synthesis and biological evaluation of 4-arylcoumarin analogues of combretastatins. Part 2.
AID468180Selectivity index, ratio of IC50 for human THP1 cells to IC50 for Plasmodium falciparum W22010European journal of medicinal chemistry, Mar, Volume: 45, Issue:3
Synthesis and antiprotozoal activity of 4-arylcoumarins.
AID595712Cytotoxicity against drug-resistant human K562 cells overexpressing P-gp after 48 hrs by MTT assay2011Journal of medicinal chemistry, May-12, Volume: 54, Issue:9
Synthesis and biological evaluation of 4-arylcoumarin analogues of combretastatins. Part 2.
AID468179Antiplasmodial activity against multidrug-resistant Plasmodium falciparum W2 infected human erythrocytes after 48 hrs by flow cytometry2010European journal of medicinal chemistry, Mar, Volume: 45, Issue:3
Synthesis and antiprotozoal activity of 4-arylcoumarins.
AID595707Cell cycle arrest in drug-sensitive human HCT116 cells assessed as accumulation at G2/M phase at 10 uM after 24 hrs by FACS-flow cytometry (Rvb = 32+/- 3 %)2011Journal of medicinal chemistry, May-12, Volume: 54, Issue:9
Synthesis and biological evaluation of 4-arylcoumarin analogues of combretastatins. Part 2.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (5)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's2 (40.00)29.6817
2010's3 (60.00)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 12.63

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index12.63 (24.57)
Research Supply Index1.79 (2.92)
Research Growth Index4.42 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (12.63)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews1 (20.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other4 (80.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
SubstanceRelationship StrengthStudiesTrialsClassesRoles
chloroquine
Chloroquine: The prototypical antimalarial agent with a mechanism that is not well understood. It has also been used to treat rheumatoid arthritis, systemic lupus erythematosus, and in the systemic therapy of amebic liver abscesses.. chloroquine : An aminoquinoline that is quinoline which is substituted at position 4 by a [5-(diethylamino)pentan-2-yl]amino group at at position 7 by chlorine. It is used for the treatment of malaria, hepatic amoebiasis, lupus erythematosus, light-sensitive skin eruptions, and rheumatoid arthritis.		2.0510aminoquinoline;
organochlorine compound;
secondary amino compound;
tertiary amino compound		anticoronaviral agent;
antimalarial;
antirheumatic drug;
autophagy inhibitor;
dermatologic drug
raloxifene
raloxifene : A member of the class of 1-benzothiophenes that is 1-benzothiophene in which the hydrogens at positions 2, 3, and 6 have been replaced by p-hydroxyphenyl, p-[2-(piperidin-1-yl)ethoxy]benzoyl, and hydroxy groups, respectively.		3.23101-benzothiophenes;
aromatic ketone;
N-oxyethylpiperidine;
phenols		bone density conservation agent;
estrogen antagonist;
estrogen receptor modulator
naringenin
(S)-naringenin : The (S)-enantiomer of naringenin.		3.2310(2S)-flavan-4-one;
naringenin		expectorant;
plant metabolite
tosylphenylalanyl chloromethyl ketone
Tosylphenylalanyl Chloromethyl Ketone: An inhibitor of Serine Endopeptidases. Acts as alkylating agent and is known to interfere with the translation process.. N-tosyl-L-phenylalanyl chloromethyl ketone : The N-tosyl derivative of L-phenylalanyl chloromethyl ketone.		3.2310alpha-chloroketone;
sulfonamide		alkylating agent;
serine proteinase inhibitor
tamoxifen
[no description available]		3.2310stilbenoid;
tertiary amino compound		angiogenesis inhibitor;
antineoplastic agent;
bone density conservation agent;
EC 1.2.3.1 (aldehyde oxidase) inhibitor;
EC 2.7.11.13 (protein kinase C) inhibitor;
estrogen antagonist;
estrogen receptor antagonist;
estrogen receptor modulator
amphotericin b
Amphotericin B: Macrolide antifungal antibiotic produced by Streptomyces nodosus obtained from soil of the Orinoco river region of Venezuela.. amphotericin B : A macrolide antibiotic used to treat potentially life-threatening fungal infections.		2.0510antibiotic antifungal drug;
macrolide antibiotic;
polyene antibiotic		antiamoebic agent;
antiprotozoal drug;
bacterial metabolite
daidzein
[no description available]		2.02107-hydroxyisoflavonesantineoplastic agent;
EC 2.7.7.7 (DNA-directed DNA polymerase) inhibitor;
EC 3.2.1.20 (alpha-glucosidase) inhibitor;
phytoestrogen;
plant metabolite
cyclosporine
ramihyphin A: one of the metabolites produced by Fusarium sp. S-435; RN given refers to cpd with unknown MF		2.0610homodetic cyclic peptideanti-asthmatic drug;
anticoronaviral agent;
antifungal agent;
antirheumatic drug;
carcinogenic agent;
dermatologic drug;
EC 3.1.3.16 (phosphoprotein phosphatase) inhibitor;
geroprotector;
immunosuppressive agent;
metabolite
fosbretabulin
[no description available]		3.5920stilbenoid
ConditionIndicatedRelationship StrengthStudiesTrials
Carcinoma, Non-Small Cell Lung
[description not available]		02.0210
Carcinoma, Non-Small-Cell Lung
A heterogeneous aggregate of at least three distinct histological types of lung cancer, including SQUAMOUS CELL CARCINOMA; ADENOCARCINOMA; and LARGE CELL CARCINOMA. They are dealt with collectively because of their shared treatment strategy.		02.0210